CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific Sessions

Aldosterone and renin biomarker activity clinically demonstrate how baxdrostat mechanistically achieves selective blood pressure lowering effects with no impact on cortisol

Related Keywords

United States ,American ,Mason Freeman ,American Heart Association ,Cincor Pharma Inc ,Cincor Pharma ,Heart Association ,Chief Medical Officer ,Htn Trial Highlights ,Renin Activity Reinforce ,Biological Mechanism ,Dose Dependent Reduction ,Blood Pressure With Baxdrostat ,Well Tolerated Profile ,